About
Captured the Industry’s Most Exciting Developments in Complement-Based Therapeutics
The 9th year, the Complement-Based Drug Development Summit united leading experts to tackle the industry's most pressing challenges. This included exploring the use of complement-mediators as combination therapies, discovering innovative indications where complement inhibitors are being explored outside of the typical rare disease context and unlocking novel methods being used to assess the safety and efficacy of complement inhibitors.
With insights from 22+ expert speakers from Apellis, Complement Therapeutics, Sanofi, Annexon Bioscineces, Argenx and more, this summit was a comprehensive guide to defining your complement-based therapeutics strategy for 2026 and beyond. Attendee's delved into the immense opportunities presented by the next generation of life-changing therapeutics set to transform the lives of patients across hematology, ophthalmology, nephrology, oncology and more.
The Summit Saw Interactive Discussions On:
Exploring Novel Efficacy & Safety Assessments:
Attendee's delved into cutting-edge methods for evaluating complement inhibitor safety and efficacy, including case studies on complement imaging and the complement-neutrophil axis, featuring insights from Michael Holers and Annexon Biosciences
Discover Expanding Indications:
Uncovered innovative areas where complement inhibitors are being explored beyond rare diseases, such as Type 1 Diabetes, Cystic Fibrosis, and Neurodegeneration, with presentations from ArgenX and Invizius, as the field shifts its focus
Access Latest Clinical Readouts:
Attendee's immersed themselves in the most recent clinical trial results for complement inhibitors across ophthalmology, nephrology, and hematology, with updates from Apellis, Annexon, and Sanegene Bio
Deep Dive into Intracellular Complement:
Ben Afzali from NIH in a brand-new workshop explored the next generation of therapeutic targets within intracellular complement and their effects on cellular metabolism, genetic regulation, and apoptosis
Uncover a New Complement Pathway Activator:
We hear from Michael Brenner on his discovery of Granzyme K, which activates the entire complement system by cleaving C2 and C4 proteins, highlighting its promise as a future therapeutic target
What You Missed:
20+ world-class speakers and 80+ senior attendees, joined the largest community of complement-based drug development experts worldwide for the unique opportunity to deep dive into pipeline development progress, lessons learns and novel strategies to accelerate clinical progress in in complement inhibitors across a diverse set of indications, spanning nephrology, oncology, hematology, ophthalmology and more.
What Your Peers Have to Say:
“The conference was intimate which made it easier to interact with others. There were many industry experts in attendance, all focused on the topic, which meant conversations were on point and very informative.”
– Scientist
“I enjoyed the workshops very much and their interactive format.”
– Principal Scientist